An observational study in Breast Cancer and Breast Cancer (Triple Negative Type), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris — 10 open to participants now, 13 under way, none of them phase 3. Breast Neoplasms · Assistance Publique - Hôpitaux de Paris.
Among the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2026, is one of 19 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 32nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →10 of the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75 · Women only
Assistance Publique - Hôpitaux de Paris
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 72 across the 13 interventional studies, 320 across the 19 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
3 of the studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07739121Assistance Publique - Hôpitaux de ParisBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | 2026-12-31 |
| NCT05258539Assistance Publique - Hôpitaux de ParisBreast Cancer Prevention and Screening Membership | 2027-04-01 |
| NCT07687446Assistance Publique - Hôpitaux de ParisPerformance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded treatment options, yet their efficacy varies depending on tumor subtype. This non-interventional study aims to identify novel predictive biomarkers of response or resistance to these emerging therapies. The Senocohort study will prospectively collect clinical, biological, imaging, and organoid-derived data from breast cancer patients, with a focus on hormone receptor-negative tumors. The ultimate goal is to improve precision medicine strategies and patient stratification
Senocohort is a prospective, bicentric cohort study designed to collect clinico-biological data and establish a biobank of patient-derived tumor organoids (PDOs) from residual tissue samples obtained during routine care. The aim is to identify new multimodal biomarkers (molecular, cellular, and imaging) predictive of response or resistance to breast cancer therapies, with evaluation based on progression-free survival. The study targets an enriched population of hormone receptor-negative breast cancers, particularly triple-negative subtypes, which currently lack effective targeted treatments. Samples will be used for genomic analyses, PDO development, and circulating biomarker studies, with 10 years of clinical follow-up.
Patients aged 18 or older with a histologically confirmed diagnosis of breast cancer, treated at the Saint-Louis Hospital senology and breast surgery departments. Emphasis will be placed on hormone receptor-negative subtypes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with newly diagnosed or recurrent breast cancer managed at the breast surgery and senology units. Residual tumor tissue, blood, and clinical data will be collected for analysis.
Other: Patients follow-up
Blood sampling, residual tissue material collection and clinical data collection
Number of Predictive Multimodal Biomarkers identified
Discovery and validation of molecular, cellular, and imaging biomarkers associated with response or resistance to therapies, evaluated on progression-free survival.
Time frame: Up to 10 years
Overall Survival Analysis by Biomarker Subgroup
Evaluation of overall survival based on biomarker-defined subgroups.
Time frame: Up to 10 years
Multimodal biomarker performance
Assessment of the added value of combining multiple types of biomarkers (e.g., genomic + imaging).
Time frame: Up to 10 years
Drug Sensitivity in PDO Models
Ex vivo response of PDOs to approved or experimental therapies, correlated with clinical outcomes.
Time frame: Up to 10 years
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2031, 60 months later.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 60 months is close to that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →